Novavax

Results of Com-Cov Mix-and-Match Vaccine Study

The Com-Cov2 study tested the efficacy and safety of mix-and-matching COVID-19 vaccines, including Pfizer, AstraZeneca, Moderna and Novavax. Moderna or Novavax vaccines were administered 8-12 weeks after a first dose of the Pfizer or AstraZeneca vaccine, measuring for IgG antibodies at 28 days after the second dose.

Read More »

The NIH Begins Trial on Mixing COVID Vaccine Boosters

A trial funded by the NIH has entered Phase 1/2 testing to study COVID-19 vaccine boosters from different manufacturers on fully vaccinated adults. While it has not been determined whether boosters will be necessary, Dr. Fauci has stated that “we need to prepare for the possibility… to counter waning immunity and to keep pace with an evolving virus”

Read More »

U.K. Expands Clinical Trial for Mixing COVID-19 Vaccines Between Four Manufacturers

The University of Oxford has expanded its clinical trial investigating the safety and efficacy of interchanging COVID-19 vaccines. While interchanging doses will primarily reduce vaccine shortages and allow for more rapid vaccinations, countries such as Germany have already updated vaccine recommendations for mixing vaccines. Those under 60 years of age who have received the AstraZeneca vaccine are recommended to get Pfizer or Moderna for their second dose. This is in response to several dozen blood clotting cases amongst German citizens under 60 years old. 

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.